Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

Phospholipase D1 Couples CD4+ T Cell Activation to c-Myc-Dependent Deoxyribonucleotide Pool Expansion and HIV-1 Replication.

Taylor HE, Simmons GE Jr, Mathews TP, Khatua AK, Popik W, Lindsley CW, D'Aquila RT, Brown HA.

PLoS Pathog. 2015 May 28;11(5):e1004864. doi: 10.1371/journal.ppat.1004864. eCollection 2015 May.

2.

Genetic analysis of the localization of APOBEC3F to human immunodeficiency virus type 1 virion cores.

Donahue JP, Levinson RT, Sheehan JH, Sutton L, Taylor HE, Meiler J, D'Aquila RT, Song C.

J Virol. 2015 Feb;89(4):2415-24. doi: 10.1128/JVI.01981-14. Epub 2014 Dec 10.

3.

Factors associated with mortality among persistently viraemic triple-antiretroviral-class-experienced patients receiving antiretroviral therapy in the HIV Outpatient Study (HOPS).

Palella FJ Jr, Armon C, Buchacz K, Chmiel JS, Novak RM, D'Aquila RT, Brooks JT; HOPS Investigators.

J Antimicrob Chemother. 2014 Oct;69(10):2826-34. doi: 10.1093/jac/dku190. Epub 2014 Jun 16.

PMID:
24942257
4.

Lower HIV provirus levels are associated with more APOBEC3G protein in blood resting memory CD4+ T lymphocytes of controllers in vivo.

De Pasquale M, Kourteva Y, Allos T, D'Aquila RT.

PLoS One. 2013 Oct 16;8(10):e76002. doi: 10.1371/journal.pone.0076002. eCollection 2013.

5.

APOBEC3G expression and hypermutation are inversely associated with human immunodeficiency virus type 1 (HIV-1) burden in vivo.

Kourteva Y, De Pasquale M, Allos T, McMunn C, D'Aquila RT.

Virology. 2012 Aug 15;430(1):1-9. doi: 10.1016/j.virol.2012.03.018. Epub 2012 May 12.

6.

Risk factors for symptomatic hyperlactatemia and lactic acidosis among combination antiretroviral therapy-treated adults in Botswana: results from a clinical trial.

Wester CW, Eden SK, Shepherd BE, Bussmann H, Novitsky V, Samuels DC, Hendrickson SL, Winkler CA, O'Brien SJ, Essex M, D'Aquila RT, DeGruttola V, Marlink RG.

AIDS Res Hum Retroviruses. 2012 Aug;28(8):759-65. doi: 10.1089/AID.2011.0303. Epub 2012 Jun 1.

7.

Signals in APOBEC3F N-terminal and C-terminal deaminase domains each contribute to encapsidation in HIV-1 virions and are both required for HIV-1 restriction.

Song C, Sutton L, Johnson ME, D'Aquila RT, Donahue JP.

J Biol Chem. 2012 May 11;287(20):16965-74. doi: 10.1074/jbc.M111.310839. Epub 2012 Mar 28.

8.

APOBEC3G complexes decrease human immunodeficiency virus type 1 production.

Martin KL, Johnson M, D'Aquila RT.

J Virol. 2011 Sep;85(18):9314-26. doi: 10.1128/JVI.00273-11. Epub 2011 Jul 13. Erratum in: J Virol. 2012 Aug;86(16):8916.

9.

Filamin A protein interacts with human immunodeficiency virus type 1 Gag protein and contributes to productive particle assembly.

Cooper J, Liu L, Woodruff EA, Taylor HE, Goodwin JS, D'Aquila RT, Spearman P, Hildreth JE, Dong X.

J Biol Chem. 2011 Aug 12;286(32):28498-510. doi: 10.1074/jbc.M111.239053. Epub 2011 Jun 24.

10.

Tenofovir (TDF)-selected or abacavir (ABC)-selected low-frequency HIV type 1 subpopulations during failure with persistent viremia as detected by ultradeep pyrosequencing.

D'Aquila RT, Geretti AM, Horton JH, Rouse E, Kheshti A, Raffanti S, Oie K, Pappa K, Ross LL.

AIDS Res Hum Retroviruses. 2011 Feb;27(2):201-9. doi: 10.1089/aid.2010.0077. Epub 2010 Oct 7.

PMID:
20929395
11.

Workshop on immunizations in older adults: identifying future research agendas.

High KP, D'Aquila RT, Fuldner RA, Gerding DN, Halter JB, Haynes L, Hazzard WR, Jackson LA, Janoff E, Levin MJ, Nayfield SG, Nichol KL, Prabhudas M, Talbot HK, Clayton CP, Henderson R, Scott CM, Tarver ED, Woolard NF, Schmader KE.

J Am Geriatr Soc. 2010 Apr;58(4):765-76. doi: 10.1111/j.1532-5415.2010.02772.x.

PMID:
20398161
12.

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

Paredes R, Lalama CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, Meyer WA 3rd, Johnson VA, Fiscus SA, D'Aquila RT, Gulick RM, Kuritzkes DR; AIDS Clinical Trials Group (ACTG) A5095 Study Team.

J Infect Dis. 2010 Mar;201(5):662-71. doi: 10.1086/650543.

14.

Differences in APOBEC3G expression in CD4+ T helper lymphocyte subtypes modulate HIV-1 infectivity.

Vetter ML, Johnson ME, Antons AK, Unutmaz D, D'Aquila RT.

PLoS Pathog. 2009 Feb;5(2):e1000292. doi: 10.1371/journal.ppat.1000292. Epub 2009 Feb 6.

15.

Survival, plasma HIV-1 RNA concentrations and drug resistance in HIV-1-infected Haitian adolescents and young adults on antiretrovirals.

Charles M, Noel F, Leger P, Severe P, Riviere C, Beauharnais CA, Miller E, Rutledge J, Bang H, Shealey W, D'Aquila RT, Gulick RM, Johnson WD Jr, Wright PF, Pape JW, Fitzgerald DW.

Bull World Health Organ. 2008 Dec;86(12):970-7.

16.

Increased detectability of plasma HIV-1 RNA after introduction of a new assay and altered specimen-processing procedures.

Rebeiro PF, Kheshti A, Bebawy SS, Stinnette SE, Erdem H, Tang YW, Sterling TR, Raffanti SP, D'Aquila RT.

Clin Infect Dis. 2008 Nov 15;47(10):1354-7. doi: 10.1086/592693.

17.

The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation.

Donahue JP, Vetter ML, Mukhtar NA, D'Aquila RT.

Virology. 2008 Jul 20;377(1):49-53. doi: 10.1016/j.virol.2008.04.017. Epub 2008 May 21.

18.

Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects.

Kuritzkes DR, Lalama CM, Ribaudo HJ, Marcial M, Meyer WA 3rd, Shikuma C, Johnson VA, Fiscus SA, D'Aquila RT, Schackman BR, Acosta EP, Gulick RM.

J Infect Dis. 2008 Mar 15;197(6):867-70. doi: 10.1086/528802.

19.

Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro.

Koelsch KK, Liu L, Haubrich R, May S, Havlir D, G√ľnthard HF, Ignacio CC, Campos-Soto P, Little SJ, Shafer R, Robbins GK, D'Aquila RT, Kawano Y, Young K, Dao P, Spina CA, Richman DD, Wong JK.

J Infect Dis. 2008 Feb 1;197(3):411-9. doi: 10.1086/525283.

20.

Multilocus genetic interactions and response to efavirenz-containing regimens: an adult AIDS clinical trials group study.

Motsinger AA, Ritchie MD, Shafer RW, Robbins GK, Morse GD, Labbe L, Wilkinson GR, Clifford DB, D'Aquila RT, Johnson VA, Pollard RB, Merigan TC, Hirsch MS, Donahue JP, Kim RB, Haas DW.

Pharmacogenet Genomics. 2006 Nov;16(11):837-45.

PMID:
17047492
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk